Physician profile
Rachel E Casseday
NPI 1538554019
$1,242.47
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $468 · 2020: $78.69 · 2021: $251 · 2022: $429 · 2024: $15.85.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $15.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $15.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $350.05 | 2019-2022 | |
| Novo Nordisk INC | $256.38 | 2019-2022 | |
| Abbvie INC. | $128.93 | 2021-2024 | |
| Amgen INC. | $85.73 | 2019-2022 | |
| Lilly USA, LLC | $68.18 | 2020-2022 | |
| Glaxosmithkline, LLC. | $60.46 | 2019-2022 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $47.26 | 2022 | |
| Abbott Laboratories | $41.23 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $40.09 | 2019-2021 | |
| Amarin Pharma, INC. | $38.02 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $28.46 | 2019-2022 | |
| Allergan, INC. | $24.88 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $16.55 | 2021 | |
| Sanofi-Aventis U.S. LLC | $16.19 | 2022 | |
| Pfizer INC. | $13.70 | 2022 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $13.37 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $12.99 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rachel Casseday listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.